- Report
- October 2025
- 150 Pages
Global
From €4270EUR$4,850USD£3,694GBP
- Report
- September 2025
- 150 Pages
Global
From €4270EUR$4,850USD£3,694GBP
- Report
- October 2025
- 150 Pages
Global
From €4270EUR$4,850USD£3,694GBP
- Report
- May 2026
- 262 Pages
Global
From €6158EUR$6,995USD£5,327GBP
- Directory
- May 2026
Global
From €1717EUR$1,950USD£1,485GBP
- Report
- February 2026
- 130 Pages
Global
From €4270EUR$4,850USD£3,694GBP
- Report
- February 2026
- 240 Pages
Global
From €3180EUR$3,613USD£2,751GBP
€3741EUR$4,250USD£3,237GBP
- Report
- January 2026
- 209 Pages
Global
From €1629EUR$1,850USD£1,409GBP
- Report
- January 2026
- 280 Pages
Global
From €3180EUR$3,613USD£2,751GBP
€3741EUR$4,250USD£3,237GBP
- Report
- November 2025
- 135 Pages
Global
From €4270EUR$4,850USD£3,694GBP
- Report
- August 2025
- 200 Pages
United States
From €2192EUR$2,490USD£1,896GBP
- Report
- February 2026
- 150 Pages
United States
From €4270EUR$4,850USD£3,694GBP
- Report
- December 2025
- 150 Pages
United States
From €4270EUR$4,850USD£3,694GBP
- Report
- October 2025
- 96 Pages
Middle East
From €4270EUR$4,850USD£3,694GBP
- Report
- October 2025
- 81 Pages
Asia Pacific
From €4270EUR$4,850USD£3,694GBP
- Report
- October 2025
- 98 Pages
Middle East
From €4270EUR$4,850USD£3,694GBP
- Report
- September 2023
- 249 Pages
Global
From €4726EUR$5,556USD£3,950GBP
- Report
- February 2020
- 360 Pages
Global
From €4313EUR$4,899USD£3,731GBP
- Report
- March 2025
- 468 Pages
Global
From €4225EUR$4,799USD£3,655GBP
- Report
- February 2025
- 138 Pages
Global
From €2000EUR$2,434USD£1,791GBP

The Checkpoint Inhibitors market is a subset of the Oncology Drugs market, which focuses on treatments for cancer. Checkpoint Inhibitors are a type of immunotherapy, which works by blocking certain proteins that act as “checkpoints” in the body’s immune system. By blocking these checkpoints, the body’s immune system is able to recognize and attack cancer cells. This type of therapy has been found to be effective in treating a variety of cancers, including melanoma, non-small cell lung cancer, and bladder cancer.
The Checkpoint Inhibitors market is highly competitive, with many companies developing and marketing their own products. Some of the major players in the market include Merck, Bristol-Myers Squibb, Roche, AstraZeneca, and Pfizer. Show Less Read more